Angie Puño

happiness is a butterfly 🦋 Lana Del Rey coded. poetry and medicine 🩵

[Angie Puño @Angiepu2]

Tú y yo siempre seremos eternas. ❤️🙏 Gracias por llegar a mi vida y por formar parte de cada etapa. Te amo infinitamente ❤️

[Angie Puño @Angiepu2]

I’m glad to have met you. I’m glad to see you. I’m glad to find you talking and doing what makes you happy every day. I’m glad you’ve influenced me in this way. I’m glad to have you in my life. Whatever this is.

[Angie Puño @Angiepu2]

Si he construido una identidad alrededor del sufrimiento, ¿recuperarme implica perder una parte de mí?

[Rohit Malde @roxboxfix]

1st Line EGFR + mNSCLC Rx options
Thinking beyond Flaura

Resistance Mechanisms

2nd Line Rx Options

Sequencing Evolving
More options evolving

[Dr Rupam Manna MD @DrRupamOncology]

Stage II/III Melanoma Management — The 2026 Update 🧵

The management paradigm has shifted beyond surgery alone.

✅ Wide local excision with appropriate margins
✅ SLNB for T1b and above
✅ No routine completion lymph node dissection (MSLT-II)
✅ Adjuvant anti–PD-1 therapy for high-risk resected disease
✅ Dabrafenib + Trametinib for BRAF V600-mutant Stage III
✅ Neoadjuvant immunotherapy (NADINA, SWOG S1801) is redefining the standard for resectable macroscopic Stage III melanoma with response-adapted treatment.

A concise infographic summarizing current evidence, landmark trials, and exam pearls for oncology trainees.

#Melanoma #SkinCancer #MedicalOncology #Oncology #Immunotherapy #Neoadjuvant #Pembrolizumab #Nivolumab #Ipilimumab #BRAF #TargetedTherapy #Surgery #ESMO #ASCO #DrNB #DMMedicalOncology #MedEd #FOAMed #CancerEducation #OncologyTwitter #CancerConceptsExplained

[Dr Rupam Manna MD @DrRupamOncology]

🧬 Advanced Melanoma (Stage IV/Unresectable): High-Yield Management Algorithm

Immunotherapy is the preferred first-line treatment for all patients, irrespective of BRAF mutation status. Remember the key sequencing pearl from DREAMseq: Immunotherapy first → Targeted therapy later (unless rapid disease control is required).

Also covers:
✅ CheckMate-067
✅ RELATIVITY-047
✅ DREAMseq
✅ COMBI-d/COMBI-v
✅ CheckMate-204
✅ Lifileucel (TIL therapy)
✅ Brain metastases management
✅ Common exam mistakes & revision pearls

Perfect for DrNB Medical Oncology, DM, ESMO & board exam revision.

#Melanoma #SkinCancer #MedicalOncology #Oncology #Immunotherapy #TargetedTherapy #BRAF #Nivolumab #Ipilimumab #Relatlimab #Lifileucel #CancerEducation #FOAMed #MedEd #DrNB #DMOncology #ESMO #ASCO #OncoTwitter #CancerConceptsExplained

[≽^• ˕ • ྀི≼ @areeeyaaarrr]

me when i finally stand up for myself but end up crying instead 🥹

[Angie Puño @Angiepu2]

🌹🌹🌹🌷🌷🌷🌻🌻🌹🌹🌹🌹

[Dilo con dibujos @dilocondibujos_]

Yo aguantándome las ganas de contestar mal:

[Rohit Malde @roxboxfix]

Capecitabine + Oxaliplatin
Chemo Regimen

COLORECTAL cancers

Doses
Indications
Toxicity and Grading
Dose Reductions and Stopping Rules

A simple Glance for Oncologists in Clinics

[Erman Akkus @Erman_Akkus]

🏥TNT strategies in rectal cancer

#cancer #oncology #MedX @OncoAlert

[MV Chandrakanth @ChandrakanthMv]

The MONARCH Trials — The Complete Abemaciclib Story

From metastatic HR+/HER2− breast cancer to high-risk early breast cancer, HER2-positive disease, and CDK4/6 inhibitor continuation beyond progression, the MONARCH program has defined the clinical role of abemaciclib across the breast cancer continuum.

This infographic provides a one-glance visual summary of the key MONARCH trials and their major clinical take-home messages.

What trial from the MONARCH program has had the greatest impact on your clinical practice?

#BreastCancer #bcsm #Oncology #MedTwitter #Abemaciclib #CDK46 #MONARCH #MedicalEducation #MVOnco

[Félicité & Sebastián @verspoem]

A veces pienso que una de las mayores muestras de cariño es la curiosidad. Preguntar, escuchar, recordar detalles. Hay personas que dicen quererte y nunca han sentido interés por descubrir quién eres realmente.

[MV Chandrakanth @ChandrakanthMv]

How long do our landmark melanoma therapies keep patients alive?

A simple memory aid for the approximate median overall survival reported in pivotal trials:

1.5 → 2 → 3 → 4.5 → 6 years

• Ipilimumab
• Dabrafenib + Trametinib*
• Nivolumab
• Nivolumab + Relatlimab†
• Nivolumab + Ipilimumab

This is not a head-to-head comparison—each value comes from different pivotal trials with different patient populations and follow-up. It's simply a practical way to remember the magnitude of benefit achieved across the evolution of metastatic melanoma therapy.

*BRAF V600-mutant melanoma only.
†Approximate landmark OS from 5-year follow-up; mature median OS has not yet been formally reported.

Which number do you remember first: 1.5, 2, 3, 4.5, or 6?

#Melanoma #Oncology #MedTwitter #FOAMed #Immunotherapy #BRAF #MedicalOncology #MVOnco

[Mauricio Ambriz @AmbrizMau]

Evaluación y tratamiento de la deficiencia de hierro:

JAMA 2025;333(20):1813-1823.

[Angie Puño @Angiepu2]

I’m a graveyard of his intentions

[Angie Puño @Angiepu2]

Pretty sad for a girl so in love 🥀